Medpace (NASDAQ:MEDP – Get Free Report) and Quantum-Si (NASDAQ:QSI – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.
Volatility and Risk
Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 3.24, indicating that its stock price is 224% more volatile than the S&P 500.
Institutional and Insider Ownership
78.0% of Medpace shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medpace | $2.53 billion | 6.83 | $451.12 million | $17.06 | 36.29 |
| Quantum-Si | $2.44 million | 70.92 | -$101.34 million | ($0.46) | -1.72 |
Medpace has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Medpace and Quantum-Si’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medpace | 17.67% | 110.15% | 24.84% |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
Analyst Ratings
This is a summary of current ratings and price targets for Medpace and Quantum-Si, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medpace | 0 | 10 | 3 | 0 | 2.23 |
| Quantum-Si | 1 | 1 | 1 | 0 | 2.00 |
Medpace currently has a consensus price target of $584.18, suggesting a potential downside of 5.63%. Quantum-Si has a consensus price target of $1.00, suggesting a potential upside of 26.49%. Given Quantum-Si’s higher probable upside, analysts plainly believe Quantum-Si is more favorable than Medpace.
Summary
Medpace beats Quantum-Si on 10 of the 14 factors compared between the two stocks.
About Medpace
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
